Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon

Journal of Dermatology

Volumn 38, Issue 5, 2011, Pages 479-481

  Barut, Sener ^a   Yuksek, Jale ^a   Sezer, Engin ^a   Gunal, Ozgur ^a   Koseoglu, Dogan ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

chronic hepatitis B; drug eruption; morbilliform; pegylated interferon; interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; PREDNISOLONE; STEROID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACK; CASE REPORT; DERMOEPIDERMAL JUNCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHIL; ERYTHEMA; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LYMPHOCYTE; MACULOPAPULAR RASH; MEASLES LIKE RASH; PHYSICAL EXAMINATION; REMISSION; SCORING SYSTEM; SKIN BIOPSY; SKIN PRURITUS; TREATMENT DURATION; TRUNK; VASCULITIS;

EID: 79955474092     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01088.x     Document Type: Article

References (10)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
3. van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005; 21: 1163-1171. (Pubitemid 40646544)
4. Marcellin P, Lau GK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 477-485. (Pubitemid 351411133)
5. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
6. Lübbe J, Kerl K, Negro F, Saurat JH,. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol 2005; 153: 1088-1090. (Pubitemid 41540797)
7. Manjõn-Haces JA, Vázquez-Lõpez F, Gõmez- Díez S, et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol 2001; 81: 223. (Pubitemid 32800479)
8. Cottoni F, Bolognini S, Deplano A, et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol 2004; 84: 120-123. (Pubitemid 38523746)
9. Veldt BJ, Schalm SW, Janssen HL,. Severe allergic eczema due to pegylated alfa interferon may abate after switching to daily conventional alfa-interferon. J Clin Gastroenterol 2007; 41: 432. (Pubitemid 46573076)
10. Milkiewicz P, Yim C, Pache I, Heathcote J,. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol 2005; 19: 677-678. (Pubitemid 43013520)